teferrol and Hemochromatosis

For the noninvasive liver iron quantification by MRI in human iron overload diseases, fundamental proton relaxation mechanisms were studied in aqueous solutions with ferritin and other iron compounds, in experimentally iron overloaded rats, and in patients with iron overload diseases. MR-relaxation rates as a function of iron concentrations in the range of 0-7.5 mg Fe/g aqueous iron solutions, 0-5.4 mg Fe/g rat liver in vivo, and 0.16-4.9 mg Fe/g human liver in vivo were determined from multi- and sets of single-spin echo sequences (1.5 T imager). As predicted by theory, transverse relaxation rates (1/T2) in aqueous iron solutions, in liver tissue of rats, and in human liver tissue increased linearly with the iron concentration. A preliminary calibration for the liver iron quantification by MRI was performed from in vivo measurements of liver 1/T2-relaxation rates and liver iron quantification by atomic absorption spectroscopy in biopsies from 13 patients. With the single spin-echo method, precise in vivo liver iron quantification in humans also above 2.0 mg Fe/g liver tissue (T2 < 15 ms) should be accomplished on any imager with shortest spin-echo time available, at least TE < 20 ms.

Topics: Adult; Animals; Calibration; Female; Ferric Compounds; Ferritins; Ferrous Compounds; Hemochromatosis; Humans; Image Enhancement; Iron; Iron-Dextran Complex; Liver; Magnetic Resonance Imaging; Male; Metallocenes; Middle Aged; Models, Biological; Models, Chemical; Organometallic Compounds; Quaternary Ammonium Compounds; Rats; Rats, Wistar; Solutions; Spectrophotometry, Atomic

Iron absorption was directly compared between equivalent doses of ferrous salts and a polymaltose complex using a twin-isotope technique in which each individual acts as his own control. In the first study, bioavailability of iron from ferrous sulfate and the complex was defined at physiologic doses of 5 mg (Group 1: n = 14) and therapeutic doses of 50 mg (Group 2: n = 13). In Group 1, mean absorption from salt was 47.77% (SD 14.58%) and from polymaltose, 46.56% SD 17.07%). In Group 2, mean absorption from salt was 32.92% (SD 13.42%) and from polymaltose, 27.07% (SD 6.50%). In a second study, 100 mg of iron in a chewable formulation was used to compare absorption between equal doses of ferrous fumarate and the polymaltose complex. Mean absorption from salt was 10.25% (SD 6.89%) and from polymaltose 10.68% (SD 4.68%). At all three dosage levels, iron is equally available from salt or polymaltose for hemoglobin synthesis (p greater than 0.20), and absorption negatively correlated with plasma ferritin (p less than 0.01). These two materials may be used interchangeably in the treatment of patients with absolute iron deficiency.

Topics: Absorption; Biological Availability; Ferric Compounds; Ferritins; Ferrous Compounds; Hemochromatosis; Humans; Iron; Iron Radioisotopes; Tablets